Table 2 Comparison of baseline characteristic between the TACE (n = 42) and non-TACE (n = 42) groups after propensity score matching.
Variables | TACE group | non-TACE group | p value |
|---|---|---|---|
Age (years) | 60.74 ± 9.57 | 58.38 ± 11.22 | 0.303 |
Gender, male | 30 (71.4%) | 26 (61.9%) | 0.355 |
Primary tumour site | |||
Pancreas | 6 (14.3%) | 5 (11.9%) | 0.977 |
Stomach | 12 (28.6%) | 11 (26.2%) | |
Endometrium | 0 | 0 | |
Chorion | 0 | 0 | |
Colorectum | 11 (26.2%) | 11 (26.2%) | |
Ovaries | 1 (2.4%) | 2 (4.8%) | |
Bile ducts | 2 (4.8%) | 0 | |
Lung | 3 (7.1%) | 2 (4.8%) | |
Kidney | 0 | 1 (2.4%) | |
Duodenum | 2 (4.8%) | 2 (4.8%) | |
Breast | 1 (2.4%) | 2 (4.8%) | |
Oesophagus | 1 (2.4%) | 2 (4.8%) | |
Gallbladder | 0 | 1 (2.4%) | |
Others | 3 (7.1%) | 3 (7.1%) | |
Numbers of hepatic metastases | |||
One | 2 (4.8%) | 6 (14.3%) | 0.085 |
Two | 0 | 2 (4.8%) | |
More | 30 (71.4%) | 30 (71.4%) | |
Unknown | 10 (23.8%) | 4 (9.5%) | |
Other transfers | |||
Lymph gland | 6 (14.3%) | 11 (26.2%) | 0.088 |
Other organs | 6 (14.3%) | 11 (26.2%) | |
Unknown | 30 (71.4%) | 20 (47.6%) | |
Hypertension | 9 (21.4%) | 10 (23.8%) | 0.794 |
Diabetes | 3 (7.1%) | 2 (4.8%) | 0.645 |
CHD | 3 (7.1%) | 3 (7.1%) | 1 |
Smoking | 16 (38.1%) | 17 (40.5%) | 0.823 |
Hepatitis | 0 | 0 | |
Child-Pugh score | 5.24 ± 0.69 | 5.14 ± 0.57 | 0.492 |
Child-Pugh classification | |||
A | 38 (90.5%) | 40 (95.2%) | 0.676 |
B | 4 (9.5%) | 2 (4.8%) | |
AST | 32.14 ± 19.25 | 39.19 ± 38.80 | 0.295 |
TBIL | 16.49 ± 17.66 | 22.53 ± 39.63 | 0.369 |
Albumin | 39.77 ± 5.59 | 37.88 ± 6.35 | 0.152 |
PT | 14.20 ± 18.04 | 12.11 ± 1.79 | 0.456 |
APTT | 30.12 ± 3.13 | 29.69 ± 3.20 | 0.536 |
INR | 1.01 ± 0.10 | 1.04 ± 0.12 | 0.184 |
Ascites | 0 | 1 (2.4%) | 0.314 |
RFA | 5 (11.9%) | 5 (11.9%) | 1 |
